BIOMAT Database Logo BIOMAT Database Logo

Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea. 1999

F Lori, and J Lisziewicz
Research Institute for Genetic and Human Therapy, Washington, DC, USA. RIGHT@gunet.georgetown.edu

Virus life cycles depend on cellular factors. Therefore, targeting cellular in combination with viral enzymes could be an effective control in virus replication. In contrast to viral proteins, cellular proteins are not prone to mutations; therefore, viral escape is not expected from drugs inhibiting cellular factors. Hydroxyurea inhibits the cellular enzyme ribonucleotide reductase, thus reducing DNA synthesis. Furthermore, this drug potentiates the activity of nucleoside analogues, inhibits the escape of A-analogue resistant mutants, and increases the phosphorylation of T-analogues. Besides its antiviral activity, hydroxyurea effects the immune system by decreasing immune activation, inhibiting the expansion of CD8 cells and the depletion of CD4 cells. Hydroxyurea has been used in medicine for 40 years, is well tolerated, and it is the least expensive available anti-HIV-1 drug. These characteristics make hydroxyurea a primary candidate for use in combination therapies for the treatment of HIV-1 infection.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D004197 Disease Reservoirs Animate or inanimate sources which normally harbor disease-causing organisms and thus serve as potential sources of disease outbreaks. Reservoirs are distinguished from vectors (DISEASE VECTORS) and carriers, which are agents of disease transmission rather than continuing sources of potential disease outbreaks. Humans may serve both as disease reservoirs and carriers. Disease Reservoir,Human Disease Reservoirs,Infectious Disease Reservoir,Reservoirs of Infection,Infectious Disease Reservoirs,Disease Reservoir, Human,Disease Reservoir, Infectious,Disease Reservoirs, Human,Human Disease Reservoir,Infection Reservoir,Infection Reservoirs,Reservoir, Disease,Reservoir, Infectious Disease,Reservoirs, Human Disease
D004261 DNA Replication The process by which a DNA molecule is duplicated. Autonomous Replication,Replication, Autonomous,Autonomous Replications,DNA Replications,Replication, DNA,Replications, Autonomous,Replications, DNA
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

F Lori, and J Lisziewicz
Inhibition of human immunodeficiency virus type-1 by cdk inhibitors.
March 2010, AIDS research and therapy,
F Lori, and J Lisziewicz
Inhibition of human immunodeficiency virus type-1 integrase by curcumin.
April 1995, Biochemical pharmacology,
F Lori, and J Lisziewicz
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
February 2003, Antimicrobial agents and chemotherapy,
F Lori, and J Lisziewicz
Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition.
June 2020, Heliyon,
F Lori, and J Lisziewicz
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by daphnodorins.
September 1994, Antiviral research,
F Lori, and J Lisziewicz
Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives.
October 2002, Antimicrobial agents and chemotherapy,
F Lori, and J Lisziewicz
Hydroxyurea to inhibit human immunodeficiency virus-1 replication.
February 1999, Pharmacotherapy,
F Lori, and J Lisziewicz
Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
June 2002, Human gene therapy,
F Lori, and J Lisziewicz
Inhibition of human immunodeficiency virus type-1 through autophagy.
June 2013, Current opinion in microbiology,
F Lori, and J Lisziewicz
Inhibition of human immunodeficiency virus type 1 RNase H by sulfated polyanions.
December 1989, Journal of virology,
Copied contents to your clipboard!